DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

OCT 28 1998

NDA 20-668/S-003

Astra Pharmaceuticals, L.P.
Attention: Daniel J. Cushing, Ph.D.
725 Chesterbrook Blvd.
Wayne, PA 19087-5677

Dear Dr. Cushing:

Please refer to your supplemental new drug application dated December 19, 1997, received December 22, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lexxel (enalapril maleate/felodipine ER) Tablets.

We acknowledge receipt of your submissions dated June 25, August 28 and October 2, 1998. Your submission of October 2, 1998 constituted a full response to our June 19, 1998 action letter.

This supplemental new drug application provides for the manufacture of an alternative combination tablet containing 5 mg enalapril maleate and 2.5 mg felodipine.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted labeling text. Accordingly, this supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert and immediate container and carton labels submitted October 5, 1998). Marketing the products with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed to each application. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 20-668/S-003." Approval of these submissions by FDA is not required before the labeling is used. Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact:

Mr. David Roeder
Regulatory Health Project Manager
(301) 594-5313

Sincerely yours, /S/ 12/19/98

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc:
Archival NDA 20-668
HFD-110/Div. Files
HFD-110/D.Roeder
HF-2/MedWatch (with labeling)
HFD-002/ORM (with labeling)
HFD-101/ADRA (with labeling)
HFD-40/DDMAC (with labeling)
HFD-613/OGD (with labeling)
HFD-95/DDMS (with labeling)
HFD-810/DNDC Division Director
DISTRICT OFFICE

Drafted by: dlr/October 8, 1998
Initialed by: F Zielinski/10/9/98
K Srinivasachar/10/9/98
A Karkowsky/10/14/98
N Morgenstern/10/23/98
final:sb/10/26/98
filename: 20668s003ap981007

APPROVAL (AP)

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER
20-668/S-003

Approvable Letter

NDA 20-668/S-003

Astra Pharmaceuticals, L.P.
Attention: Daniel J Cushing, Ph.D.
725 Chesterbrook Blvd.
Wayne, PA 19087-5677

Dear Dr. Cushing:

Please refer to your supplemental new drug application dated December 19, 1997, received December 22, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lexxel (enalapril maleate – felodipine) ER Tablets (5-5 mg).

We acknowledge receipt of your amendments dated April 1, April 16, 1998 and the resubmission dated August 28, 1998. The resubmission is a complete response to the FDA letter dated June 19, 1998.

The supplemental application provides for the manufacture of an alternative combination tablet containing 5 mg enalapril maleate and 2.5 mg felodipine.

We have completed review of this supplemental application, as amended, and it is approvable. Before this application is approved, it is necessary for you to submit final printed labeling.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

Sincerely yours,

Kasturi Srinivasachar, Ph.D.
Chemistry Team Leader, DNDC I
Division of Cardio-Renal Drug Products (HFD-110)
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc: Original NDA 20-668 S-003
HFD-110 Division File
HFD-110 Project Manager, Dave Roeder
HFD-810 Review Chemist, Florian Zielinski, 9/4/98
HFD-92 DDMS
HFD-810, DNDC I Division Director, Charles Hoiberg
DISTRICT OFFICE

Drafted by: FWZ/Sept 4, 1998
Initialed by: Kasturi Srinivasachar
Final:

Approval Date: 12/27/96

APPROVABLE